Form 4: Xeris Biopharma CFO Exercises Stock Options

Xeris Biopharma Holdings, Inc. Chief Financial Officer Steven Pieper exercised stock options to acquire 41,927 shares of common stock in a planned transaction.

Summary

• Steven Pieper, Chief Financial Officer of Xeris Biopharma Holdings, Inc., exercised stock options on March 5, 2026.
• He acquired 27,891 shares of common stock at an exercise price of $4.09 per share. These options were granted on December 10, 2020, under the Company's 2018 Stock Option/Stock Issuance Plan.
• He also acquired 14,036 shares of common stock at an exercise price of $5.93 per share. These options were granted on January 31, 2018, under the Company's 2011 Stock Option/Stock Issuance Plan.
• Following these transactions, Steven Pieper beneficially owns 1,408,940 shares of common stock directly.
• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the CFO is increasing his direct ownership in the company, which can indicate confidence in future performance, especially when executed under a 10b5-1 plan.

Positives

• The Chief Financial Officer is increasing his direct ownership in the company by exercising stock options, which can signal confidence in the company's future prospects.
• The exercise prices ($4.09 and $5.93) are below the implied current market price (as options are typically exercised when in-the-money), indicating a potential gain for the officer.
• The transactions were conducted under a Rule 10b5-1 plan, suggesting a pre-planned, non-discretionary transaction.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive option exercises are a common form of equity compensation, aligning management's interests with shareholders. The use of a Rule 10b5-1 plan indicates a pre-arranged transaction, which helps mitigate concerns about opportunistic insider trading, a standard practice in corporate governance.

Comparison to Industry Standards

• Executive stock option plans are a standard component of compensation packages across various industries, including biotechnology and pharmaceuticals, similar to practices at companies like Pfizer, Johnson & Johnson, or Amgen.
• The vesting schedules (e.g., 50% on first anniversary, 50% on second; or 25% on first anniversary, then monthly over three years) are typical for incentivizing long-term employee retention and performance, comparable to those seen in tech companies like Microsoft or financial institutions like JPMorgan Chase.
• The exercise of options when they are in-the-money is a common occurrence for executives seeking to realize value from their compensation, a practice observed across the S&P 500.

Stakeholder Impact

• Shareholders: Increased alignment of management's interests with shareholders due to increased direct ownership.
• Employees: May signal stability and confidence in the company's leadership and future.

Key Dates

Recommendation

While the CFO's exercise of options and increased ownership is a positive signal of confidence, a Form 4 filing alone typically does not provide enough comprehensive financial or strategic information to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await more comprehensive financial reports or strategic updates for a more complete investment picture.

Keywords

Xeris Biopharma Holdings, XERS, Steven Pieper, CFO, Stock Options, Insider Transaction, Form 4, Equity Compensation, 10b5-1 Plan, Beneficial Ownership